The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Molecular MRD as a prognostic marker for AML patients with mutated CEBPA
Peter Valk, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, highlights measurable residual disease (MRD) as a prognostic marker for some patients with CEBPA-mutated acute myeloid leukemia (AML). This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
